Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | HRH1 | P35367 | 6/20 | 0.38 |
| ▸ | HRH2 | P25021 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12120505 | 0.86 | CYP2C19 (0.62) | CYP2C19ALOX15TSHRHRH1HRH2 | |
| SCHEMBL21078258 | 0.80 | HTR1A (0.46) | CYP2C19TSHRHRH1CHRM3CHRM1 | |
| SCHEMBL28898592 | 0.80 | CYP2C19 (0.43) | CYP2C19TSHRHRH1HRH2LMNA | |
| SCHEMBL20053331 | 0.79 | ALOX15 (0.50) | CYP2C19ALOX15HRH1HRH2ALDH1A1 | |
| SCHEMBL20857027 | 0.78 | CYP2C19 (0.61) | CYP2C19TSHRLMNAUSP2HDAC2 | |
| SCHEMBL22287259 | 0.77 | CYP2C19 (0.43) | CYP2C19TSHRHRH1HRH2LMNA | |
| SCHEMBL7503597 | 0.76 | SLC6A3 (0.44) | CYP2C19TSHRHRH1CHRM3CHRM1 | |
| SCHEMBL20857024 | 0.76 | CYP2C19 (0.55) | CYP2C19TSHRHRH1HRH2LMNA | |
| SCHEMBL26308166 | 0.75 | ALDH1A1 (0.46) | CYP2C19TSHRLMNAUSP2CHRM1 | |
| SCHEMBL27630987 | 0.74 | TDP1 (0.46) | TSHRHRH1CHRM3CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599599-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4578508-A2 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | Medicon Pharmaceuticals, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-3687972-B1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-117417281-A | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2024-01-19 | — | — | CN | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | disclosed |
| CN-111655666-B | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2023-11-07 | — | — | CN | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | MEDICON PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-111655666-A | Anti-inflammatory, anti-cancer and anti-angiogenic compounds, pharmaceutical compositions and methods of making and using the same | 麦迪康制药公司 | 2020-09-11 | — | — | CN | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICON PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3687972-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | Medicon Pharmaceuticals, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067974-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICALS COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | MEDICAL PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599599-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, SLC10A6, LITAF | CYP2C19 978/4885ALOX15 1570/4885TSHR 4015/4885 |
| US-20200246330-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885ALOX15 7/4885TSHR 4882/4885 |
| US-11752146-B2 | Anti-inflammatory, anti-cancer, and anti-angiogenic compounds, pharmaceutical compositions, and methods of making and using thereof | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885ALOX15 7/4885TSHR 4882/4885 |
| US-20240016799-A1 | ANTI-INFLAMMATORY, ANTI-CANCER, AND ANTI-ANGIOGENIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEREOF | VEGFA, HPGDS, ALOX5 | CYP2C19 666/4885ALOX15 7/4885TSHR 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.